Soochow Securities·2025-10-12 11:34Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Viewpoints - The impact of the tariff war on the pharmaceutical sector is limited, with a positive outlook on innovation and domestic substitution [1][16] - The ranking of favored sub-industries is: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [2][10] - Specific stock recommendations include Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Dong'e Ejiao from the traditional Chinese medicine sector, and Yuyue Medical and United Imaging Healthcare from the medical device sector [2][11] Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date increase of 21.87%, while the Hang Seng Biotechnology Index has increased by 94.11% [5][10] - Recent stock performance highlights include Zhend Medical (+21.00%) and Wanbangde (+12.01%) in A-shares, while Hong Kong stocks like Kaisa Health (+48.84%) have also performed well [5][10] Tariff Policy Analysis - The U.S. tariff policy on pharmaceuticals is expected to have minimal impact on China's pharmaceutical industry, as most exports consist of raw materials [16][22] - The tariff primarily affects brand-name and patented drugs, while generic drugs and raw materials are largely exempt [16][19] R&D Progress and Company Dynamics - Significant advancements in innovative drug development include the initiation of Phase III clinical trials for the first selective CDK2 inhibitor and breakthroughs in ADC treatments for triple-negative breast cancer [5][10] - The report emphasizes the importance of research quality and efficiency in CRO services, which remain unaffected by tariff policies [16][22] Market Performance Review - The pharmaceutical index's P/E ratio stands at 39.05, slightly above historical averages, indicating a robust market outlook despite recent fluctuations [5][10] - The report notes that the recent stock price declines in the innovative drug sector are primarily driven by market sentiment rather than fundamental changes [22]